Positron emission tomography molecular imaging for drug development.
about
Lost in Translation (LiT): IUPHAR Review 6Recent Advances in the Development and Application of Radiolabeled Kinase Inhibitors for PET ImagingImportance of relating efficacy measures to unbound drug concentrations for anti-infective agentsEvaluation of the Efficacy of Targeted Imaging AgentsPrecision Medicine in Multiple Sclerosis: Future of PET Imaging of Inflammation and Reactive AstrocytesIn vivo imaging of microglial activation by positron emission tomography with [(11)C]PBR28 in the 5XFAD model of Alzheimer's diseaseSimplified programming and control of automated radiosynthesizers through unit operations.Structural optimization of Zn(II)-activated magnetic resonance imaging probes.Ethanolic carbon-11 chemistry: the introduction of green radiochemistry.Radiosyntheses using fluorine-18: the art and science of late stage fluorinationNuclear imaging: a powerful novel approach for tuberculosis.Application of Positron Emission Tomography in Drug Development.EGFR-expression in primary urinary bladder cancer and corresponding metastases and the relation to HER2-expression. On the possibility to target these receptors with radionuclides.Automated radiochemical synthesis and biodistribution of [¹¹C]l-α-acetylmethadol ([¹¹C]LAAM).Tissue distribution of pretomanid in rat brain via mass spectrometry imaging.Precision Nanomedicine Using Dual PET and MR Temperature Imaging-Guided Photothermal Therapy.Sodium-22-radiolabeled silica nanoparticles as new radiotracer for biomedical applications: in vivo positron emission tomography imaging, biodistribution, and biocompatibilityDevelopment of 1-N-(11)C-Methyl-L- and -D-Tryptophan for pharmacokinetic imaging of the immune checkpoint inhibitor 1-Methyl-Tryptophan.Digital Microfluidics: A New Paradigm for Radiochemistry.Two-photon Fluorescence Anisotropy Microscopy for Imaging and Direct Measurement of Intracellular Drug Target Engagement.Determining target engagement in living systemsNew frontiers in the design and synthesis of imaging probes for PET oncology: current challenges and future directions.18F labeling of arenes.In vitro, in vivo and in silico models of drug distribution into the brain.Fluorine-18 patents (2009-2015). Part 1: novel radiotracers.Considerations in the Development of Reversibly Binding PET Radioligands for Brain Imaging.Use of PET Imaging to Evaluate Transporter-Mediated Drug-Drug Interactions.The use of hyperpolarized carbon-13 magnetic resonance for molecular imaging.Tactics for preclinical validation of receptor-binding radiotracers.Total-body imaging: Transforming the role of positron emission tomography.Fluorine-18 labelled building blocks for PET tracer synthesis.Synthesis of (18) F-Difluoromethylarenes from Aryl (Pseudo) HalidesAsymmetric 18F-fluorination for applications in positron emission tomography.Visualization of biodistribution of Zn complex with antidiabetic activity using semiconductor Compton camera GREISynthesis of Diverse (11)C-Labeled PET Radiotracers via Direct Incorporation of [(11)C]CO2.Quantitating drug-target engagement in single cells in vitro and in vivo.CETSA quantitatively verifies in vivo target engagement of novel RIPK1 inhibitors in various biospecimens.Late-stage [(18)F]Fluorination: New Solutions to Old ProblemsEditors' pick 2012.In Vivo Bacteriophage Biodistribution.
P2860
Q24289150-DC2A9BF5-4775-4A89-B46E-C3A0E4616EDEQ26774478-8AE04C6C-3FE5-41FB-A144-069D91860343Q26827380-6A3482F4-968E-461D-B41A-4DA95073236FQ28074924-88E2D3D7-F8AF-444F-854C-DD6A7E56A68DQ28078621-DA13C534-BBF7-44EF-9BB3-0ECAAFFE0F71Q28274003-13DC0E57-BB98-4042-AF56-04FFCCAAE9D0Q30541615-BB4B413D-3F9F-4BAF-9200-90889AB229CCQ30650060-9FD30A12-6FFB-484F-BD13-2BD326C94E3DQ33671283-5D47A3AD-9289-4333-B580-0031905EA781Q34074437-9074575C-814E-49BD-AC8A-1C013F64F215Q34315731-46065A4F-67B8-47B6-BCB3-8A6833E27DE7Q34398539-8C1897EB-57BC-4309-92FD-EE1C57CEB55CQ35184816-678CC425-3574-426F-9911-941E04CD5723Q35258947-A156AF2F-04FD-41CC-BF82-BE1DDF98E8A4Q35710470-BFAC8085-FF6A-49F1-B1CE-4FCAB6603B0DQ36047731-9185025D-F142-4666-A4E4-A96D979F23CCQ36160430-E6E0838D-0C94-408D-A96A-F314C7BE1774Q36265787-3FBB16F6-1122-4D12-9E76-A4C92BEB3748Q36526022-9AF22E03-5608-4FA2-A957-95D059E6FDAAQ37098162-714FCE32-1494-4482-9A5D-4A2548C0E4AEQ37732146-8A20FA13-7378-4FAE-B6AE-E206E3171AD7Q38040666-CF48210B-13D7-402E-ADFC-17016F76A1CEQ38053980-FE4902C3-642D-43FF-B7CD-079A044C0074Q38081102-7C3BD00A-7160-4BB9-8732-63D7BB4CD9FAQ38670162-5F39D01C-D3A0-43B4-948B-12216512EE72Q38810544-1F13628E-0E28-4C8F-BBB8-5A028F211226Q38844653-36CD1D90-A7C3-496E-A968-0BD0F1DE397CQ38947519-AD8BF156-666D-49F0-84EE-7A7C04C3C6C6Q38984519-0A0484FD-7397-4672-93E7-6F4E56BE2AEEQ39180679-1EE3713C-94A1-4EEC-A1B2-29302B766875Q39369099-7D68E0D3-F53C-4D8E-8AB9-1DCC16ABB382Q39978269-F04D39F9-B6E3-4626-832D-0D0E7C204449Q41174141-FF549849-3F1A-4757-91D9-F0CF40BA511DQ41683371-7C95E793-A3AF-4BE6-B8A3-F6053B1E3690Q42011591-8B199809-0A9B-4993-8FCB-3A75F6FAD783Q42275555-01BB43D5-E8BC-4D1C-B20F-1DAE173E419CQ42376104-D80FD4B4-B7C7-4B38-B601-F9E745D8B082Q42615427-93D7666B-01B1-4A78-87D7-90FD209FA163Q42976095-0537E3E0-DAB4-4655-BC79-28C68AB0976FQ43033569-D0E26CC3-F5F6-4E18-ACA0-28BA48E3E84E
P2860
Positron emission tomography molecular imaging for drug development.
description
2012 nî lūn-bûn
@nan
2012 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Positron emission tomography molecular imaging for drug development.
@ast
Positron emission tomography molecular imaging for drug development.
@en
type
label
Positron emission tomography molecular imaging for drug development.
@ast
Positron emission tomography molecular imaging for drug development.
@en
prefLabel
Positron emission tomography molecular imaging for drug development.
@ast
Positron emission tomography molecular imaging for drug development.
@en
P2860
P50
P1476
Positron emission tomography molecular imaging for drug development.
@en
P2093
Eugenii A Rabiner
Jan Passchier
P2860
P304
P356
10.1111/J.1365-2125.2011.04085.X
P407
P577
2012-02-01T00:00:00Z